Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic adipose-derived mesenchymal stem cells for diabetic critical limb ischemia
2018-002653-29Phase 2Active
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Jul 2022
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI) comparing Allogeneic adipose-derived mesenchymal stem cells with Placebo (2 arms). Primary endpoint: Safety and tolerability of intramuscular allogeneic adipose-derived mesenchymal stem cells. Started Jul 2022; status: active.
02
Drugs
CSCC_ASC
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2018-002653-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002653-29.